Project Funding Details

Adjuvant development for human vaccination against cancer
Alt. Award Code
Funding Organization
Worldwide Cancer Research
Budget Dates
2011-06-01 to 2014-05-31
Principal Investigator
Munz, Christian
University of Zurich
Europe & Central Asia
Zürich, CH


View People Map
This project funding has either no collaborators or the information is not available.

Technical Abstract

Successful vaccination in humans relies on the right choices of antigen and adjuvant, of which the second can only poorly be modelled in traditional small animal models due to the differential distribution of pathogen associated molecular pattern (PAMP) receptors in rodents and man, which need to be engaged by adjuvants. Therefore, this proposal aims to compare novel small animal models with human or mouse immune system components for their reactivity towards established adjuvants, to which mice and men react differently, and towards new adjuvants, which might elicit immune reactivity in both species or humans preferentially. Recognition of these adjuvants by antigen presenting cells, primarily dendritic cells (DCs; Aim 1), their ability to assist priming of T cell responses against antigens of the human tumorvirus Epstein Barr virus (EBV; Aim 2), and protection against lymphoma formation by challenge with EBV (Aim 3) will be evaluated. These experiments should allow us to identify adjuvants, which trigger human DCs to induce protective T cell responses against B cell lymphomas induced in vivo by the human tumorvirus EBV.

Cancer Types

  • Hodgkin's Disease
  • Non-Hodgkin's Lymphoma
  • Pharyngeal Cancer

Common Scientific Outline (CSO) Research Areas

  • 3.4 Prevention Vaccines